In our previous studies, we successively demonstrated the promising activity of dacomitinib in patients with NSCLC carrying uncommon EGFR mutations in first-line and later-line settings and the manageable safety profile of dacomitinib [16,17,18]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.